Abstract:Glioblastoma (GBM) is an incurable primary malignant neoplasm of the central nervous system. GBM as an electrically active neoplasm diffusely colonizes healthy brain tissues, disrupting the neurotransmission balance and causing glioma-related epilepsy (GRE) in up to 50% of patients. Interestingly, GRE is an independent favorable prognostic factor for survival in GBM. The therapeutic induction of seizure may have a previously unexplored oncologic value in GBM. We have previously reported in CT-2A-bearing mice subjected to daily extrinsic electrical modulation (EEM) diminished tumor progression and increased overall survival relative to sham-treated mice, but the mechanism by which EEM produces its anti-tumor effect remains uncertain. Therefore, GBM-bearing mice (CT-2A cells xenografted into 5-7 weeks old C57BL/6 female mice, n=5/group) received either a single EEM of 2.0 millicoulombs (mC) or sham treatment. The mice were terminated at 3 hours, 24 hours, 4, 7, and 10 days post-EEM, and tumors and contralateral brain cortex were analyzed using bulk RNA-sequencing and Sequential immunofluorescence (SeqIF TM ). SeqIF TM revealed how EEM activates neuronal activity via cFOS expression and induces tumor-specific cell damage through cleaved caspase-3 expression, without affecting healthy brain tissue. Furthermore, RNA-seq performed post-EEM revealed gene expression changes of not only synapse organization markers but also of several tumor-tumor and tumor-neuron connectivity key markers, such as growth-associated protein 43 (GAP43), neuroligin-3 (NLGN3), and glutamate receptors such as GRIA4 and GRIN1 between others. However, the expression of these markers diminished significantly 96h after-EEM, indicating a reduction in intercellular electrical communication by the inhibition of the neoplasm cells electrical integration with neuronal circuits by downregulating glutamatergic receptor expression, blocking the synapse-forming protein NLGN3, and the network-connecting protein GAP43. Taken together, our findings reveal how by the disruption of these critical interactions within the tumor microenvironment though EEM impacts on GBM growth making it more susceptible to therapeutic interventions.

Malignant glioma remodeling of neuronal circuits: therapeutic opportunities and repurposing of antiepileptic drugs

Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits

Relevance for Novel Treatment Strategies in Low- and High-Grade Gliomas

Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors

Seizures in low- and high-grade gliomas: current management and future outlook

The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions

Electrical and synaptic integration of glioma into neural circuits

Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication

Cnsc-57. The Role Of Neuron-To-Glioma Synaptic Communication In Therapeutic Resistance

The complex molecular epileptogenesis landscape of glioblastoma

Exth-35. Repurposing Of Clinically Approved Glutamate Antagonists To Treat Glioblastoma

Seizures in glioma patients: An overview of incidence, etiology, and therapies

Cnsc-45. Extrinsic Electrical Modulation Impacts Glioblastoma Tumor Growth By Disrupting Its Intercellular Communication

Drug Repurposing in Pediatric Brain Tumors: Posterior Fossa Ependymoma and Diffuse Midline Glioma under the Looking Glass

Postoperative seizure control in patients with tumor-associated epilepsy

Glioma synapses recruit mechanisms of adaptive plasticity

Extra-temporal pediatric low-grade gliomas and epilepsy

Epilepsy and brain tumors: Two sides of the same coin

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management

The efficacy and safety of novel antiepileptic drugs in treatment of epilepsy of patients with brain tumors

Metabotropic glutamate receptors (mGluRs) in epileptogenesis: an update on abnormal mGluRs signaling and its therapeutic implications